Avis Budget Group, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian J. Choi
- Full Time Employees
- 17,000
- Sector
- Industrials
- Industry
- Rental & Leasing Services
- Address
- 6 Sylvan Way Parsippany NJ United States of America 07054
- IPO Date
- Sep 14, 1983
- CIK
- 0000723612
- Website
- avisbudgetgroup.com
- Similar Companies
- Business
- Avis Budget Group, Inc. operates as a global provider of mobility solutions through three leading brands: Avis, Budget, and Zipcar. The company specializes in car rental services including standard car and truck rentals, corporate and leisure vehicle rentals, and on-demand car-sharing services primarily through its Zipcar brand. Its product offerings include a diverse fleet ranging from economy to premium and luxury vehicles, cargo vans, moving trucks (under Budget Truck), and specialty rentals such as child safety seats and GPS navigation systems. Avis Budget Group caters to a broad customer base including leisure and business travelers, event planners, and governments, operating extensively across North America, Europe, and select international markets. Founded in 1946 and headquartered in Parsippany, New Jersey, the company has developed value-added services such as Avis First, a premium car rental product introduced in 2025, which provides frictionless curbside pick-up and drop-off with dedicated concierge services. Recent strategic developments within the last two years include the launch of Avis First, reflecting a shift towards a premium service model intended to enhance customer experience and operational excellence. Avis Budget Group has focused on fleet modernization with a disciplined approach to vehicle acquisition, including managing the impact of vehicle recalls on fleet utilization and depreciation. The company emphasizes technological innovation through partnerships, notably with Waymo, to advance autonomous vehicle fleet management. Additionally, it has undertaken focused cost discipline measures to sustain profitability amid a mixed demand environment, especially addressing challenges in commercial and government segments. Future outlook anticipates growth aligned with key global events in 2026, including the World Cup and America's 250th anniversary, aimed at driving increased demand and revenue. Avis Budget Group maintains a significant presence through its integrated rental, truck, and car-sharing platforms, leveraging an extensive, connected vehicle fleet. It reinforces its market position through ongoing customer experience enhancements, digital innovation including artificial intelligence for service personalization, and strategic operational adjustments to meet evolving mobility needs worldwide. Recent executive management realignment in 2024 further reflects the company’s focus on financial discipline and growth execution. In summary, Avis Budget Group combines comprehensive vehicle rental solutions, premium service offerings, robust fleet management, and innovative technology partnerships to serve a diversified global customer base in the mobility industry. Its latest initiatives underscore a strategic pivot to upscale customer experience while maintaining operational efficiency and preparing for key market demand drivers in the near future.
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
These 10 Stocks Are Getting Crushed By Short Sellers Right Now
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Why Is Avis Budget (CAR) Down 3.2% Since Last Earnings Report?
A Look at Avis Budget Group Inc (CAR) After 5.9% Gain -- GF Value $130.88 vs Price $174.88
CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities
Avis Budget Group Announces Pricing of $300 Million of Senior Notes
TTEC vs. Avis Budget: Which Turnaround Stock is Better Positioned?
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
Avis Budget Group Announces Intention to Offer $300 Million of Senior Notes
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Qihan Biotech Announces FDA Clearance of IND for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases